Our results show that DFMO can reduce MYCN protein levels in MYCN2 (+) cells, in spite of Akt/PKB activation, as shown by p27Kip1 accumulation, providing a molecular rationale for the use of DFMO in NB tumors with high MYCN expression. This evidence concerns the gene CDKN1B and neuroblastoma.